NASDAQ
21.09.26 | 18:01
1,705 US-Dollar
+1,19 % +0,020
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.09. | ALX Oncology auf H.C. Wainwright Konferenz: Zwei Wirkstoffkandidaten vor entscheidenden Tests | 3 | Investing.com Deutsch | ||
| 10.09. | ALX Oncology auf Gesundheitskonferenz von Cantor: Biomarker-Strategie rückt in den Fokus | 1 | Investing.com Deutsch | ||
| 06.08. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | ALX Oncology GAAP EPS of -$0.13 | 1 | Seeking Alpha | ||
| 06.08. | ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 723 | GlobeNewswire (Europe) | - On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive... ► Artikel lesen | |
| 06.08. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 30.06. | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | 3 | GlobeNewswire (USA) | ||
| 30.06. | ALX Oncology names Scott Garland chairman, adds general counsel | 1 | Investing.com | ||
| 30.06. | ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel | 2 | GlobeNewswire (USA) | ||
| 26.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 3 | SEC Filings | ||
| 11.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Earnings Call: ALX Oncology übertrifft Gewinnprognose für Q1 2026 | 1 | Investing.com Deutsch | ||
| 09.05. | Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS | 1 | Seeking Alpha | ||
| 08.05. | ALX Oncology: 100 % Ansprechrate in Studie bestätigt CD47-Strategie | 6 | Investing.com Deutsch | ||
| 08.05. | ALX Oncology Q1 2026 slides: 100% response validates CD47 strategy | 3 | Investing.com | ||
| 08.05. | ALX Oncology GAAP EPS of -$0.17 beats by $0.02 | 1 | Seeking Alpha | ||
| 08.05. | ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update | 728 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable... ► Artikel lesen | |
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression | 274 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,794 | +1,11 % | Evotec-Aktie +5%: Nur ein Strohfeuer oder der Beginn des Rebounds? | Die Kursentwicklung der Evotec-Aktie war zuletzt ein einziges Desaster. Innerhalb der letzten zwölf Monate halbierte sich der Kurs des Wirkstoffforschungsunternehmens und am Dienstag dieser Woche sackte... ► Artikel lesen | |
| MODERNA | 146,54 | +9,36 % | Moderna und BioNTech lassen Corona endgültig hinter sich | Aus dem alten Duell der beiden Corona-Gewinner ist ein neuer Wettbewerb geworden. Moderna erlebt nach überzeugenden Phase-3-Daten für eine personalisierte Krebstherapie eine spektakuläre Neubewertung.... ► Artikel lesen | |
| NOVAVAX | 9,090 | +3,41 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| CRISPR THERAPEUTICS | 50,95 | +3,47 % | CRISPR Therapeutics auf Morgan Stanley Konferenz: Pipeline-Erweiterung und kommerzielle Fortschritte | ||
| INOVIO PHARMACEUTICALS | 1,058 | -1,76 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,680 | +0,95 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,272 | -4,23 % | Defence Therapeutics Inc.: Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders | Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,420 | +2,98 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 55,74 | +0,14 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors | SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D.... ► Artikel lesen | |
| EXELIXIS | 51,33 | +1,06 % | Citizens reiterates Exelixis stock rating on FDA review extension | ||
| HALOZYME THERAPEUTICS | 97,44 | -0,49 % | Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 | SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,540 | 0,00 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +1,77 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 125,35 | -1,49 % | Nxera Pharma's Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition | NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with NeurocrineNxera... ► Artikel lesen | |
| VAXART | 0,600 | 0,00 % | Vaxart, Inc. - 8-K, Current Report |
ALX ONCOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,705 Euro und damit +1,19 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.